Blog

Similar PD-1 inhibitors have been shown to improve the five-year survival rate of patients with advanced non-small cell lung cancer.

Experts including Dr Mothi Babu Ramalingam from Singapore General Hospital weighed in on breast cancer rehabilitation options in Singapore, including TCM.

The multi-centre Singapore study offers active surveillance to patients at high risk of developing liver cancer, with the aim of developing more accurate miRNA diagnostics for early HCC.

The therapy being trialled combines Toripalimab, an anti-PD1 immunotherapy drug developed in China, together with Bevacizumab.

Tech professional Amy Neary drew on emotional support from her family, friends and Singapore’s Breast Cancer Foundation to cope with the rigorous treatments and surgeries, plus the toll they took on her mental well-being.

Oncoshot was recognised as winner for the Health Products & Services category, for its commitment to elevate cancer treatment through technology.

The Phase II, randomised, double-blinded, placebo-controlled trial, which is being conducted at NCCS, evaluates the safety and efficacy of the Xiang Bei Yang Rong Tang decoction in reducing cancer related fatigue.

The global study explores the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE with durvalumab plus bevacizumab therapy.

The regional media outlet highlighted Oncoshot's contributions in fostering a more collaborative, data-driven cancer clinical trial landscape.

The Phase I and II single-arm pilot study with multiple cohorts of patient populations harnesses AI for personalised guidance of an individual’s dose modulations based only on his/her data. It aims to re-look at the way oncology clinical trials are designed.

Tech-powered solutions such as data-driven pre-screening tools can enable more accurate feasibility studies, thus improving cancer clinical trial enrolment rates.

He leads a Phase III, randomised, open-label study of Atezolizumab plus Bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation.

The phase III, randomised, double-blind, placebo-controlled study evaluates the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients who meet the specific trial criteria.

Oncoshot won in the Healthtech category of the Startup Awards, which honour regional startups that embody the spirit of innovation and entrepreneurship.

The free service is designed to help busy oncologists identify promising cancer clinical trials for their patients in an efficient manner.

With cancer continuing to be a leading cause of mortality worldwide, cutting-edge cancer clinical trials can help you expand your treatment options.

In light of Breast Cancer Awareness month in October, we highlight potentially live-saving detection methods and new therapies - including those you may access through clinical trials.